Who is sponsoring NCT04807439?

NCT04807439 is sponsored by Boston Scientific Corporation.

What drugs are being tested in NCT04807439?

Interventions in NCT04807439: SYNERGY XLV (Megatron) Coronary Stent System.

What condition does NCT04807439 study?

NCT04807439 studies Atherosclerosis, Heart Diseases, Coronary, Coronary Artery Disease, Cardiovascular Diseases.

Is NCT04807439 still recruiting?

NCT04807439 is currently completed. Last updated 23 October 2023.

Last reviewed 2023-10-23 · How we verify

NCT04807439

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A U.S Post Approval Study Evaluating the SYNERGY XLV (MEGATRON) Stent System

Completed Last updated 23 October 2023

What this trial tests

trial testing SYNERGY XLV (Megatron) Coronary Stent System in Atherosclerosis in 100 participants. Completed in 18 August 2023.

Timeline

14 April 2021

Primary endpoint
19 August 2022

18 August 2023

Quick facts

Lead sponsor	Boston Scientific Corporation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	100
Start date	14 April 2021
Primary completion	19 August 2022
Estimated completion	18 August 2023
Sites	8 locations across United States

Drugs / interventions tested

SYNERGY XLV (Megatron) Coronary Stent System

Conditions studied

Atherosclerosis — all drugs for Atherosclerosis →
Heart Diseases, Coronary — all drugs for Heart Diseases, Coronary →
Coronary Artery Disease — all drugs for Coronary Artery Disease →
Cardiovascular Diseases — all drugs for Cardiovascular Diseases →

Sponsor

Boston Scientific Corporation — full company profile →

Who can join

18 and older, any sex, with Atherosclerosis or Heart Diseases, Coronary. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a post-market, standard of care, real-world observational study to assess the clinical outcomes of the SYNERGY XLV (MEGATRON) Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 28 mm in length (by visual estimate) in native coronary arteries ≥3.50 mm to ≤5.00 mm in diameter (by visual estimate). This Post Approval study is a cohort associated with the Evolve 4.5/5.0 (SYNERGY LV) Post Approval Study, which is registered under ClinicalTrials.gov ID: NCT03875651.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atherosclerosis

Currently open trials in the same condition.

NCT07448038 — A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vas · Phase 2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT06788431 — A Clinical Study of IMC-001 for Injection in Improving Atherosclerotic Plaque Stability in Patients With Acute Coronary · EARLY_PHASE1 · recruiting
NCT06676046 — Natural History of Uncommon Dyslipidemias, Rare Lipid Disorders and Unusual Atherosclerotic Conditions · recruiting
NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting

Other Boston Scientific Corporation trials

Trials by the same sponsor.

NCT07458243 — Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT · not yet recruiting
NCT07458217 — Combined CM and STN Stimulation for Motor Epilepsy · NA · not yet recruiting
NCT07276815 — OverStitch NXT Endoscopic Suture System · NA · not yet recruiting
NCT07353710 — A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure · NA · not yet recruiting
NCT07195708 — Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365') · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04807439 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boston Scientific Corporation
Last refreshed: 23 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04807439.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing